Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Update

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 12,350,000 shares, a growth of 17.0% from the March 31st total of 10,560,000 shares. Based on an average daily volume of 1,620,000 shares, the days-to-cover ratio is currently 7.6 days.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ATOS. HC Wainwright reissued a "buy" rating and issued a $4.00 price target on shares of Atossa Therapeutics in a report on Tuesday, April 16th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Atossa Therapeutics in a research note on Friday, January 12th. Finally, StockNews.com downgraded shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, March 18th.

Atossa Therapeutics Stock Performance

ATOS traded up $0.01 on Friday, reaching $1.53. The company had a trading volume of 900,111 shares, compared to its average volume of 2,648,768. The business has a 50 day simple moving average of $1.44 and a 200 day simple moving average of $1.02. The company has a market cap of $191.72 million, a price-to-earnings ratio of -6.38 and a beta of 1.20. Atossa Therapeutics has a 52-week low of $0.59 and a 52-week high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last issued its quarterly earnings results on Monday, April 1st. The company reported ($0.06) EPS for the quarter. As a group, equities research analysts predict that Atossa Therapeutics will post -0.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jonathan Finn purchased 25,000 shares of the stock in a transaction dated Wednesday, April 10th. The shares were purchased at an average cost of $1.77 per share, with a total value of $44,250.00. Following the completion of the acquisition, the director now owns 25,000 shares in the company, valued at approximately $44,250. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 7.80% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Atossa Therapeutics stock. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 133,591 shares of the company's stock, valued at approximately $98,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.11% of Atossa Therapeutics at the end of the most recent reporting period. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.